SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Meusers P,Engelhard M,Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol. 1989; 7: 365380.
  • 2
    Norton AJ,Mathews J,Pappa V, et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20 year period. Ann Oncol. 1995; 6: 249256.
  • 3
    Argatoff LH,Connors JM,Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997; 89: 20672078.
  • 4
    Teodorovic I,Pittaluga S,Kluinnelemans JC, et al. Efficacy of 4 different regimens in 64 mantle cell lymphoma cases. Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol. 1995; 13: 28192826.
  • 5
    Zucca E,Roggero E,Pinotti G, et al. Patterns of survival in mantle cell lymphomas. Ann Oncol. 1995; 6: 257282.
  • 6
    Fisher RI,Dahlberg S,Nathwani BN, et al. A clinical analysis of 2 indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including mucosa-associated lymphoid tissue and monocytoid B-cell categories). a Southwest Oncology Group study. Blood. 1995; 85: 10751084.
  • 7
    Greiner TC,Moynihan MJ,Chan WC, et al. P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996; 87: 43024310.
  • 8
    Khouri IF,Romaguera J,Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol. 1998; 16: 38033809.
  • 9
    Khouri IF,Lee MS,Saliba R, et al. Non-ablative allogeneic stem cell transplantation for advanced/recurrent mantle cell lymphoma. J Clin Oncol. 2003; 21: 44074412.
  • 10
    Romaguera JE,Fayad L,Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper- CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005; 23: 70137023.
  • 11
    Stanley KE. Prognostic factors for survival in patients with inoperative lung cancer. J Natl Cancer Inst. 1980; 65: 2532.
  • 12
    Harris NL,Jaffe ES,Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology. 2000; 36: 6986.
  • 13
    Luthra R,Sarris AH,Hai S, et al. Real-time 5′->3′ exonuclease-based PCR assay for detection of the t(11;14)(q13;q32). Am J Clin Pathol. 1999; 112: 524530.
  • 14
    Katz RL,Caraway NP,Gu J, et al. Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma. Am J Clin Pathol. 2000; 114: 248257.
  • 15
    Cheson BD,Horning SJ,Coiffier B, et al. Report on an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 10: 12441253.
  • 16
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 17
    Peto R,Peto J. Asymptotically efficient rank invariant test procedures. J Roy Stat Soc. 1972; 135: 185207.
  • 18
    Shipp MA;Harrington DP, and the International Non-Hodgkin's Lymphoma Prognostic Factors Project, et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987994.
  • 19
    Foran JM,Rohatiner AZ,Cunningham D, et al. European phase 2 study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000; 18: 317324.
  • 20
    Gressin R,Legouffe E,Leroux D, et al. Treatment of mantle-cell lymphomas with the VAD ± chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation. Ann Oncol. 1997; 8( suppl 1): 103106S.
  • 21
    Kaufmann YL,Jones RJ,Diehl LF, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed or refractory mantle cell lymphoma. Blood. 2004; 104: 22692271.
  • 22
    Dang NH,Hagemeister FB,Pro B, et al. Phase 2 study of denileukin diftitox for relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004; 22: 40954102.
  • 23
    Cohen BJ,Moskowitz C,Strauss D, et al. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma. 2001; 42: 10151022.
  • 24
    Goy A,Younes A,McLaughlin P, et al. Phase 2 study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 667675.
  • 25
    O'Connor OA,Wright J,Moskowitz C, et al. Phase 2 clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005; 23: 676684.
  • 26
    Mclaughlin P,Hagemeister FB,Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996.; 14: 12621268.
  • 27
    Seymour JF,Grigg AP,Szer J,Fox RM. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol. 2001; 12: 14551460.
  • 28
    Forstpointner R,Dreyling M,Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004; 104: 30643071.
  • 29
    Levine AM,Espina BM,Mohrbacher LH, et al. Fludarabine, mitoxantrone, and rituxan: an effective regimen for the treatment of mantle cell lymphoma [abstract]. Blood. 2002; 100( suppl 1): 361A.
  • 30
    Mathias J. Rummel,Al-Batran SE,Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 33833389.
  • 31
    Fisher RI,Bernstein SH,Kahk BS, et al. Multicenter phase 2 study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006.; 24: 48674874.
  • 32
    Robak T,Smolewski P,Sebula B, et al. Rituximab combined with cladribine or with cladribina and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer. 2006; 107: 15421550.
  • 33
    Rupolo M,Michieli M,Spina M, et al. R-Dhaox, high dose chemotherapy (HDC) and rituximab maintenance as salvage treatment in relapsed or refractory (R/R) follicular (F) and mantle cell (MC) lymphomas (NHL) [abstract]. J Clin Oncol. 2007: 100( suppl 18): 450S. (Abstract 8036).
  • 34
    Drach J,Kaufmann H,Pichelmayer O, et al. Marked activity of bortezomib, rituximab and dexamethasone in relapsed and refractory mantle cell lymphoma [abstract]. Blood. 2006; 108: 779A.